 SOUTH SAN FRANCISCO, Calif., April 01, 2021 GLOBE NEWSWIRE -- Cytokinetics, Incorporated Nasdaq: CYTK today announced that on March 31, 2021 it granted stock options to purchase an aggregate of 163,700 shares of common stock to three new employees, whose employment commenced in March 2021, as a material inducement to their employment. These grants include the grant of stock options to purchase 150,000 shares of common stock to the Companys new chief commercial officer, Andrew Callos. The grant was previously approved by the Compensation and Talent Committee of Cytokinetics Board of Directors under the companys Amended and Restated 2004 Equity Incentive Plan. 